Search hospitals > Utah > Salt Lake City
Huntsman Cancer Institute/University of Utah
Claim this profileSalt Lake City, Utah 84112
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Melanoma
Conducts research for Pancreatic Cancer
1129 reported clinical trials
81 medical researchers
Summary
Huntsman Cancer Institute/University of Utah is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer and other specialties. Huntsman Cancer Institute/University of Utah is involved with conducting 1,129 clinical trials across 861 conditions. There are 81 research doctors associated with this hospital, such as Heloisa Soares, Michael Pulsipher, MD, Sunil Sharma, and Theresa Werner, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
KRAS positive
2Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
Top PIs
Heloisa SoaresHuntsman Cancer Institute/University of Utah4 years of reported clinical research
Studies Neuroendocrine Tumors
Studies Pancreatic Cancer
25 reported clinical trials
50 drugs studied
Michael Pulsipher, MDChildren's Hospital Los Angeles6 years of reported clinical research
Studies Acute Lymphoblastic Leukemia
Studies Leukemia
16 reported clinical trials
31 drugs studied
Sunil SharmaHonorHealth Research Institute1 year of reported clinical research
Studies Cancer
Studies Colorectal Cancer
16 reported clinical trials
34 drugs studied
Theresa Werner, MDHuntsman Cancer Institute/University of Utah3 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
14 reported clinical trials
24 drugs studied
Clinical Trials running at Huntsman Cancer Institute/University of Utah
Skin Cancer
Breast Cancer
Lung Cancer
Multiple Myeloma
Prostate Cancer
Esophageal cancer
Bladder Cancer
Pancreatic Cancer
Kidney Cancer
Uterine Cancer
Cemiplimab + Surgery
for Advanced Skin Cancer
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.
Recruiting2 awards Phase 37 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
IMA203
for Skin Cancer
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Huntsman Cancer Institute/University of Utah?
Huntsman Cancer Institute/University of Utah is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer and other specialties. Huntsman Cancer Institute/University of Utah is involved with conducting 1,129 clinical trials across 861 conditions. There are 81 research doctors associated with this hospital, such as Heloisa Soares, Michael Pulsipher, MD, Sunil Sharma, and Theresa Werner, MD.
Where is Huntsman Cancer Institute/University of Utah located?
The Huntsman Cancer Institute/University of Utah Hospital is situated at 1950 Circle of Hope Dr, Salt Lake City, UT 84112, on the University of Utah campus's northeast corner, adjacent to Primary Children’s Hospital and University of Utah Hospital. Complimentary valet parking is provided Monday through Friday, from 7:00 am to 5:30 pm.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at Huntsman Cancer Institute/University of Utah hospital, contact the Billing Office at 801-587-6303 or 800-862-4937. For assistance with your bill, reach out to a financial advocate at 801-581-2957. For online billing consultations, schedule an appointment or call 801-587-6303.
What insurance does Huntsman Cancer Institute/University of Utah accept?
The Huntsman Cancer Institute/University of Utah accepts a wide range of insurance plans, such as SelectHealth Medicare Advantage, Aetna, American Health Plans, Blue Cross Blue Shield, and Cigna. SelectHealth Medicare Advantage members benefit from access to the Huntsman Cancer Institute through the SelectHealth Medicare Advantage Network Expansion. Additionally, the University of Utah Health collaborates with most major health insurance carriers and transplant networks.
What awards or recognition has Huntsman Cancer Institute/University of Utah received?
Huntsman Cancer Institute at the University of Utah is recognized as the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West, serving a broad region. It boasts a distinguished history of cancer genetics research, leveraging the Utah Population Database, the largest of its kind in the U.S., to identify genetic patterns of cancer in families. The institute leads in discovering genes for inherited cancers and operates the most extensive Phase 1 clinical cancer research program in the Mountain West, offering around 325 clinical trials.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.